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Betydelse av mitogen-aktiverade proteinkinaser i mastcell-mediator inducerad 
luftvägshyperresponsivitet i marsvinstrakea  
 
Bakgrund: Allergenexponering orsakar aktivering av mastceller och frisättning av deras mediatorer, 
vilket leder till sammandragning av luftvägar. Luftvägshyperresponsivitet (LHR) är en av 
grundpelarna i astma och idag finns ingen fullständig förståelse för orsakerna bakom detta fenomen. 
Det finns teorier som förklarar LHRs uppkomst med upprepade sammandragningar, inflammation, och 
förändringar i osmolalitet. En annan teori är att LHR beror på förändringar i signalering via mitogen-
aktiverade proteinkinaser (MAPK). Syfte: Syftet med detta projekt var att undersöka om ovalbumin 
(OVA) kan orsaka LHR mot mastcellsmediatorer och klarlägga om MAPK bidrar till denna process. 
Material och Metoder: Marsvin sensitiserades mot OVA genom en intraperitoneal injektion varpå 
cirkulära segment av marsvinstrakea dissekerades ut och inkuberades med eller utan OVA och 
hämmare av c-Jun N-terminal kinase (JNK), extracellular-signal-regulated kinase/MAPK (MEK) och 
p38. Trakeasegmenten monterades i ett organbad i en myograf för att mäta tensionen i dessa efter 
tillsättning av mastcellsmediatorer och karbakol. Data från varje segment och agonist korrelerades till 
den maximala kraftutvecklingen detta segment åstadkommit och presenterades som 
medelvärde±medelfel. Resultat: exponering för OVA orsakade LHR mot histamin i trakeasegmenten 
(p<0.05; pEC50 6.5±0.1) jämfört med ingen exponering för OVA (pEC50 6.2±0.1). Inkubation med 
JNK MAPK hämmare, men inte med p38 och MEK hämmare motverkade LHR mot histamin. 
Slutsats: LHR mot histamin kan induceras i en ex vivo marsvinsmodell och kan motverkas med 
hämning av signalvägen JNK. 
 
Involvement of mitogen-activated protein kinases in mast cell mediator induced airway hyper-
responsiveness in guinea pig trachea 
 
Introduction: Exposure to allergens causes activation of mast cells and release of its mediators leading 
to airway constriction. Airway hyper-responsiveness (AHR) is a major characteristic of asthma but 
understanding of its causes is incomplete. Theories include repetitive airway constriction, 
inflammation or changes in osmolality. Another theory is that AHR is mediated through changes in 
mitogen-activated protein kinases (MAPK) signalling pathways. Aims: To determine the ability of 
ovalbumin (OVA) to induce AHR to mast cell mediators and to determine the contribution of MAPK 
to AHR. Material and Methods: Guinea pigs (GP) were sensitized to OVA by intra-peritoneal 
injection, thereafter circular segments of GP trachea were dissected and incubated in presence or 
absence of OVA and inhibitors of c-Jun N-terminal kinase (JNK), extracellular-signal-regulated 
kinase/MAPK (MEK) and p38. Thereafter, segments were mounted on a myograph in organ baths in 
order to measure the tension in trachea after addition of mast cell mediators and carbachol. The data 
from each segment and agonist was related to maximal contraction of that segment and presented as 
mean±SEM. Results: Exposure to OVA induced AHR to histamine in tracheal segments (p<0.05; 
pEC50 6.5±0.1) as compared to no OVA exposure (pEC50 6.2±0.1). Incubation with MAPK JNK 
inhibitor, but not with MAPK p38 and MEK inhibitors reduced OVA-induced AHR to histamine. 
Conclusions: AHR to histamine can be induced in a GP trachea ex vivo model and it can be reduced 
by inhibition of MAPK JNK. 
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5-LOX – 5-lipoxygenase 
AHR – airway hyper-responsiveness 
ASM – airway smooth muscle 
DMSO – dimethyl sulfoxide 
ERK - extracellular-signal-regulated kinase 
GP – guinea pig 
GPCR – G-protein coupled receptor 
GPT – guinea pig trachea 
IgE – immunoglobulin E 
JNK – c-Jun N-terminal kinase 
LTE4 – leukotriene E4 
MAPK – mitogen-activated protein kinases 
MEK – ERK/MAPK 





Asthma is a globally prevalent heterogeneous conductive airway disease characterized by 
variable and recurring symptoms, reversible airflow obstruction, chronic airway inflammation 
and airway hyper-responsiveness (AHR) (1). 
Epidemiology and global impact 
The asthma diagnosis is based on the clinical characteristics of wheezing, shortness of breath, 
chest tightness and cough that vary over time and in intensity. The prevalence of doctor 
diagnosed disease is today around 300 million people worldwide (1). Since the middle of the 
20th century the prevalence has been reported to be increasing, though most recent studies 
indicate that the increase in prevalence among adolescents is in fact abating. In contrast, in 
countries with a high urbanization rate or areas with low income, the prevalence is increasing 
(2). This indicates that while the differences in global prevalence are decreasing, the total 
burden of the disease worldwide is increasing. However, time trends have been difficult to 
evaluate due to varying inclusion criteria and questionnaires, but also due to increased 
awareness and improved diagnostic activities (2).  
The lifetime risk of developing asthma is around 35%, comparable to the risk of developing 
cancer or coronary heart disease. In contrast with other chronic diseases, asthma tends to 
develop early and causes life-long suffering (3). Estimates show that asthma is responsible for 
about 1 in 250 deaths worldwide. For asthmatics the number of lost disability-adjusted life 
years is comparable to patients with diabetes or liver cirrhosis (4). In conclusion, asthma is a 
highly prevalent disease that burdens both patients and global health. 
Pathogenesis of asthma 
Although mechanisms of the disease are not fully understood, a complex interaction between 
environmental and genetic factors is considered to contribute to the development of asthma.  
Airway inflammation 
The stimulus that activates a symptomatic asthmatic attack can be inhalation of allergens, 
pollutants or viral infections (5). Acute inflammation starts when the allergen activates mast 
cells via crosslink of the cell-bound allergen-specific Immunoglobulin E (IgE) molecule with 
a receptor on the mast cell (6). This activates several intracellular cascades inside the mast 
cell, causing it to de-granulate. The granula contain several preformed biologically active 
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mediators, among them histamine and proteases (6). Histamine is known to act on four 
different receptors, activation of which causes bronchoconstriction and increase in mucus 
secretion (7). Another process that is induced in the mast cell is the activation of the enzymes 
cyclooxygenase and and 5-lipoxygenase (5-LOX) yielding increased production and release 
of prostaglandins and leukotrienes (6). This part of the inflammation process is called the 
early phase and results in acute airway smooth muscle (ASM) contraction and mucus 
production within minutes, leading to limitation of airflow (8). 
In some patients the early phase resolves within hours, but around half of asthmatics 
experience a second wave of obstruction. Referred to as the late phase, it develops within 2-6 
hours and peaks at 12 hours after the early phase (9).  This phase is characterized by 
recruitment of other inflammatory cells (eosinophil, neutrophil and T-helper type 2 cells) (10) 
through chemokines and cytokines, IgE production leading to a slowly developing ASM 
contraction (6). This response can be prevented by prophylactically blocking IgE (11) and 
leukotrienes (12), which suggest a contribution of mast cells.  
Repetitive or continuous exposure to allergens can lead to chronic inflammation (6). Typical 
changes in the airways are referred to as airway remodelling and include an up-regulated 
inflammatory environment (6), loss of epithelial integrity, mucus cell metaplasia, fibrosis and 
increased ASM mass. The result is constant airway narrowing due to increased ASM size, 
mucus plugging and airway hyper-responsiveness (13). The role for the mast cell in these 
processes is not yet defined. 
Airway hyper-responsiveness 
AHR is, together with inflammation, a central attribute of asthma, defined as an excessive 
airway narrowing due to stimuli that normally do not affect healthy individuals. The stimuli 
may be physical (cold air or exercise), pharmacological substances or pollutants (14). Clinical 
assessment of AHR is done by provocation with histamine or methacholine, which cause an 
acute bronchoconstriction in affected individuals (15). Carbachol is, like methacholine, a 
nonselective muscarinic receptor agonist, which is in contrast to acetylcholine is not degraded 
by acetylcholinesterase, which results in a long-lasting and sustainable contraction (16). AHR 
is considered to have a persistent component, described as a baseline AHR that most chronic 
asthma patients suffer from, which is connected to the remodelling phenomenon. 
Superimposed on that, there is a variable component that can be induced by the acute airway 
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inflammation. Although both components have been defined, the driving mechanisms behind 
AHR remain unclear (14). 
As described above, allergens and infections can induce airway inflammation in asthmatic 
patients. However, there is evidence that a bronchospasm can occur on its own without 
inflammation (17) and mast cells can be activated through osmotic stimuli (18), adenosine or 
cytokines, independent of IgE activation (19). Moreover, isolated bronchoconstriction alone, 
without inflammation, can induce airway remodelling (20), which shows, that though AHR 
and airway inflammation are characteristic for asthma, both processes can occur 
independently.  
Airway smooth muscle contraction 
ASM cells, which encircle the airways throughout the entire bronchial tree, are considered to 
be deeply involved in AHR because of the increased sensitivity of the airways to constricting 
agents. For a long time ASM cells were considered as simply the effector cells in asthma. 
However, recent studies suggest that the ASM itself contributes to the development and 
sustainment of asthma and presumably AHR by releasing cytokines and growth factors that 
maintain airway inflammation (21). 
Methods of in vitro quantification of the smooth muscle contraction and characterization of 
different contractile and relaxant agents have been developed over many years. Tension 
measurements in ex vivo tissue containing smooth muscle using a myograph were first done 
on vessel rings (22, 23). The method was then adapted for use on bronchiole rings (24) and 
trachea rings (25). Adner et al. has shown that tracheal rings from mice can survive in culture 
for as long as 32 days without changing their physiopharmacological properties, making them 
a useful model for asthma research (25). 
Animal model for studying AHR 
Guinea pig (GP) is the most correct animal model for studying airway pharmacology. Many 
studies have shown that anatomy, physiology and pharmacology of the GP lung closely 
resembles that of human (26, 27).  As an illustration, during mast cell degranulation, mice and 
rats release serotonin while both humans and GP release histamine (8). The ovalbumin GP 
sensitization model used in this project has been developed during the past 30 years and has 
been shown to induce acute airway inflammation, late phase inflammation and AHR in the 
animals, modelling an asthmatic airway (26). The first encounter with the allergen does not 
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produce any symptoms. However, it induces the process of IgE-production to the specific 
allergen. When the animal encounters the same allergen again, the produced IgE-molecules 
activate the early phase of inflammation (6). 
Mitogen-activated protein kinases  
Mitogen-activated protein kinases (MAPK) are ubiquitous and well conserved cellular 
proteins, whose function is to transduce signals from outside of a cell, like inflammation or 
stress, into the cell by protein phosphorylation (28).  MAPK are phosphorylated in the cytosol 
and activated by MAPK kinases, which are activated by MAPK kinase kinases, which in turn 
are activated at the level of G-proteins at the cell membrane (29). The existence of several 
intermediates allows amplification of the signal as the amount of substrates increases for each 
level. Moreover, it allows for interplay between the different signalling pathways. The most 
well-studied signal pathways are ERK, JNK and p38 (28). 
Extracellular-signal-regulated kinase (ERK) signalling pathway  
ERK1 and ERK2 are two highly similar ubiquitous ERK isoforms at the MAPK level of the 
ERK signalling pathway, activated by different types of stimuli like growth factors, ligands 
for G-protein coupled receptors (GPCR), cytokines and osmotic stress (30). MAPK/ERK, 
shortly named MEK1 and MEK2, are two similarly efficient isoforms at the MAPK kinase 
level. MEK1 and MEK2 both phosphorylate and fully activate ERK1/2. ERK pathway is 
involved in regulating cell functions, like motility, proliferation and differentiation and are 
highly expressed in well differentiated cells, where they have been found to contribute to 
long-term potentiation of cell signalling in neurons and other highly differentiated cells (28). 
c-Jun N-terminal kinase (JNK)signalling pathway 
JNK1, JNK2 and JNK3 are structurally highly similar isoforms of JNK at MAPK level of 
JNK pathway, but have functional differences. JNK1 and JNK2 are ubiquitous, while JNK3 is 
restricted to the central nervous system. They are activated by cytokines, growth factors, 
DNA damage and environmental stressors. There are two MAPK kinases that activate JNKs, 
MEK4 and MEK7, which also have the ability to activate the p38 signalling pathway at 
higher concentrations. Activated JNK pathway contributes to the production of cytokines, 




p38 signalling pathway 
p38 is a family of four kinases α, β, γ and δ, at MAPK level of p38 pathway, which have been 
shown to have different, sometimes opposite, actions (28). p38α and p38β are ubiquitously 
expressed, while γ and δ seem to be restricted to specific tissues outside of the airways (30). 
p38 pathway can be activated by signals such as cytokines, hormones, ligands of GPCR and 
environmental stressors. MAPK kinases of p38 pathway have the ability to activate the JNK 
pathway at high concentrations (28). Due to structural and functional differences of p38 
family members, activation of p38 pathway leads to a variety of responses, such as induction 
of cell cycle checkpoints and regulation of proliferation and differentiation (30). 
Inhibitors of MAPK 
In order to block specific MAPK signalling pathways, more or less specific inhibitors have 
been developed. PD98,059 is a selective inhibitor in the ERK pathway, acting on MEK1 and 
MEK2, preventing MEK1/2 from being phosphorylated (31). SB203580 is a selective 
inhibitor of p38 pathway, acting on p38α and p38β, but not on the δ and γ isoforms (32). 1 
µM of SB203580 lowers p38α and p38β activity down to 9-13% of the original, however, it 
has also been shown to inhibit JNK2 down to 60 % of its original activity at the same 
concentration (32). SP600125 is an inhibitor of the JNK pathway, acting on JNK1 and JNK2 
isoforms. 1 µM of SP600125 lowers JNK1 and JNK2 activity down to 23-24% of the original, 
however, it has also been shown to inhibit p38α and p38β activity down to 86-89% of its 
original activity at the same concentration (32). Unfortunately, both SB202580 and SP600125 
inhibit several other, less studied, protein kinases (32, 33). 
MAPK and AHR 
Recent research has shown that MAPK JNK and ERK are involved in modulating the calcium 
response to contractile mediators in human ASM cells (34). JNK has been shown to mediate 
the elevation of extracellular calcium influx in rat bronchial segments after stimulation with 
contractile agents (35). In addition, JNK has been shown to be involved in ozone-induced 
AHR in GP (36, 37), as has p38 (36). A JNK inhibitor, SP600125, has been shown to inhibit 
AHR to OVA in sensitized mice (38). Similarly, inhibition of ERK prevented AHR to 
methacholine in mice sensitized and challenged with OVA (39). These findings point towards 
the involvement of MAPK in the formation of AHR. Yet, it is still unknown whether MAPK 
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are involved in AHR that is mediated by the most common mast cells mediators, which are 
clinically relevant in asthma. 
Aim 
The aim of the project was to study AHR in an ex vivo GPT model by determining the ability 
of OVA to induce AHR to mast cell mediators and to determine the contribution of MAPK to 
that process. 
Material and Methods 
Chemicals 
Albumin from chicken egg white (OVA) grade V, aluminium hydroxide, Krebs-Henseleit 
buffer modified (#K3753), sodium bicarbonate, dimethyl sulfoxide (DMSO) (#D5879), 
PD98,059, SB203580, SP600125, indomethacin, histamine, carbachol, leukotriene E4 (LTE4), 
potassium chloride, papaverine were purchased from Sigma-Aldrich. Sterile phosphate buffer 
solution (PBS) (#10010015), Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 
(DMEM-F12) (#11320074), Penicillin-Streptomycin (#15140122) were purchased from 
Thermo Fischer Scientific. Calcium chloride dihydrate was purchased from Merck Millipore. 
All stock solutions were made according to manufacturer’s instructions. 
Organ bath 
Tissue extraction 
Male albino GP (Dunkin-Hartley) (445-676 gram) were sensitized by a single intra-peritoneal 
injection containing 100 µg OVA and 0.1 g aluminium hydroxide dissolved in 0.8 ml sterile 
PBS.  Animals were sacrificed not earlier than 10 days later by inhalation of CO2 followed by 
removal of the trachea. Each trachea was transferred to cold Krebs-Henseleit buffer modified 
by addition of 25 mM sodium bicarbonate and 2.5 mM calcium chloride dehydrate. The 
trachea was dissected from the surrounding connective tissue and cut into eight rings of equal 
length containing between two to three cartilage rings. 
Tissue culture 
The rings were placed in a 48-well culture plate containing DMEM-F12 and 1% penicillin-
streptomycin and treated with one of the inhibitors: PD98,059 (50 µM), SB203580 (50 µM), 
SP600125 (5 µM), all dissolved in DMSO, or the vehicle, DMSO. After 40 minutes the rings 




Tracheal rings were mounted and lowered into a 5 ml tissue organ bath containing Krebs-
Henseleit buffer modified with addition of sodium bicarbonate to the concentration of 25 mM 
and calcium chloride dihydrate to the concentration 2.5 mM. The buffer was kept at 37°C and 
bubbled with carbogen (5% CO2 in O2). Changes in smooth muscle force were detected using 
an isometric force-displacement transducer linked to a grass polygraph. The response was 
displayed on a monitor using the IOX data acquisition system (EMKA, Paris, France). 
First, the rings were allowed to equilibrate in the new milieu with washes every 15 minutes 
and the resting force was gradually adjusted to 30 mN in order to create a baseline mechanical 
tension (Fig. 1). Second, 3µM of a non-selective COX-inhibitor indomethacin (dissolved in 
ethanol) was added to inhibit synthesis of prostaglandins in the tissue, since it has been 
established that they are responsible for upholding the basal tone in GPT (40). Third, 
histamine (dissolved in distilled water), a muscarinic receptor antagonist carbachol (dissolved 
in distilled water) and LTE4 (dissolved in ethanol) were added in cumulative concentrations (1 
nM to 0.1 mM) with washing and addition of indomethacin between the three substances in 
order to elicit contractions. Last, viability was assessed by contraction with 1mM histamine 
and 60 mM potassium chloride (dissolved in distilled water) followed by relaxation induced 
by 1 mM papaverine (dissolved in distilled water). 
 
Figure 1. A typical force-time trace of an experimental protocol from one tracheal segment. 
LTE4 – leukotriene E4, OVA – ovalbumin 
 
Validation of sensitization of GP 
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A successful sensitization was evaluated by a combination of two methods. One was the 
presence of white intra-peritoneal clots composed of aluminium hydroxide which indicated 
successful injections. The second was addition of OVA to the baths at the end of myograph 
measurements – if a contraction was evoked in the controls, but not in the segments incubated 
with OVA, the sensitization was considered successful (Fig. 1).  
Statistics 
The data measured in the organ baths was the force (in Newton) of the tracheal smooth 
muscle contraction and relaxation. Data collected for each segment was normalized in relation 
to the value of its strongest contraction and presented as mean ± standard error of mean. Emax 
shows the maximal response an agonist can elicit and is a measure of an agonist’s efficacy. 
pEC50 is the –log10 agonist concentration that produces 50% of the agonists maximal effect 
and is a measure of agonist’s potency. For all agonists, a non-linear regression with a variable 
slope was used to calculate Emax and pEC50. Data comparison between two groups was 
assessed by a parametric unpaired t-test. All statistical analysis was done using GraphPad 
Prism® (GraphPad Software Inc., San Diego, CA). 
Ethical considerations 
More research is needed to understand the physio-pharmacological properties of AHR in 
asthmatic individuals in order to improve the treatment options. A potential ethical problem 
with this model is that it requires whole tissue samples, implying the need to sacrifice the GP 
to be able to obtain the trachea. In order to reduce the suffering, pure CO2 was used for 
euthanasia and analgesia since it leads to very fast progressing unconsciousness and coma. 
Unconsciousness was evaluated using the pain reflexes, eyelid shutter reflex and pupil size. 
Each acquired trachea was divided to 8 pieces and several agonists were tested on the same 
tissue sample to minimize the use of animals.  
The advantage of this method is the possibility to examine the contractile pattern of the 
tracheal segments in real time using inhibitors of MAPK signalling pathways. Another 
advantage is that the outcome is pharmacological properties of mast cell mediators and the 
signalling pathways that are activated in AHR. The advantages of this study outweigh the 
ethical issues, since obtained values are clinically relevant in assessment of airway tone in 
humans and thus might lead enhanced understanding of mechanisms behind AHR.  An ethical 
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permit has been acquired (N143/14) from the regional Ethical Committee on Animal 
Experiments, Stockholm. 
Results 
Tracheal ring segments were dissected from the previously sensitized GP and incubated with 
OVA and inhibitors of different MAPK signalling pathways or vehicle, i.e. DMSO. The 
segments were mounted in organ baths where changes in ASM tone was measured by a 
myograph.   
Sensitization of GP to OVA caused AHR to histamine, but not carbachol and LTE4 
Segments incubated with OVA and DMSO were compared to those incubated without OVA 
and with DMSO. Histamine evoked a contraction in all segments (not shown), but segments 
incubated with OVA and DMSO had a significantly higher pEC50 (p<0.05) than those 
incubated without OVA (Fig. 2:A) (Tab. 1). 
A B C 
 
Figure 2. Concentration-dependent constriction of tracheal segments incubated with DMSO in 
presence or absence of OVA. The panels show dose-response curves for histamine, carbachol and 
LTE4. (A) Histamine was more potent in segments incubated with OVA than those incubated without 
OVA, n:11-12. There was no change in potency or efficacy for carbachol (B) or LTE4 (C) in 
segments treated with or without OVA, n:10-11. DMSO – dimethyl sulfoxide, OVA – ovalbumin, 
LTE4 – leukotriene E4. Data plotted from Table 1. 
 
There was no significant difference in Emax evoked by histamine between control segments 
and segments incubated with OVA (Fig. 2:A) (Tab. 1). Carbachol and LTE4 similarly evoked 
contractions in controls incubated with DMSO, though there was no significant difference in 
Emax or pEC50 between the controls and segments incubated with OVA (Fig. 2:B,C) (Tab. 1). 
ERK1/2, p38 and JNK signalling pathway inhibitors per se did not affect ASM contractions 
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pEC50 and Emax values for histamine, carbachol and LTE4 in controls incubated with different 
inhibitors were compared to controls incubated with DMSO alone. There was no significant 
difference for these values for any of the inhibitors compared to DMSO (Fig. 3) (Tab. 1). 
 
Figure 3. Contraction induced by histamine, carbachol and LTE4. The panels show dose-response 
curves for controls incubated with inhibitors or DMSO. No significant difference in either potency or 
efficacy was detected between the control segments treated with either MAPK inhibitors or DMSO, 
induced by (A) histamine, (B) carbachol or (C) LTE4. DMSO – dimethyl sulfoxide, OVA – 
ovalbumin, LTE4 – leukotriene E4. PD98,059 – MEK1/2 inhibitor, SB203580 – p38 inhibitor, 
SP600125 – JNK inhibitor. Data plotted from Table 1. 
 
Use of SP600125(JNK) but not PD98,059 (MEK1/2) and SD203580 (p38) affected the ASM 
contraction 
pEC50 and Emax values for histamine, carbachol and LTE4 in segments incubated with OVA 
and DMSO were compared to segments incubated with OVA and inhibitors. There was a 
significant difference (p<0.05) in pEC50 values induced by histamine between segments 
 
Table 1. pEC50 and Emax values for segments incubated with DMSO or inhibitors in 
presence or absence of OVA.  
Treatment 
Histamine Carbachol LTE4 
pEC50 Emax pEC50 Emax pEC50 Emax 
Control + DMSO 6.2±0.1 96.9±1.5 6.7±0.2 97.3±1.6 7.6±0.2 42.8±2.3 
OVA + DMSO 6.5±0.1* 95.3±2.6 6.7±0.2 96.7±1.7 7.5±0.1 45.8±2.5 
Control + SP600125 6.2±0.1 97.5±1.6 6.6±0.3 96.9±1.8 7.8±0.2 44.3±5.0 
OVA + SP600125 6.2±0.1 92.5±2.4 6.6±0.2 99.5±0.8 7.7±0.2 49.6±4.8 
Control + PD98,059 6.2±0.1 94.5±5.4 6.6±0.2 98.2±1.6 7.6±0.1 49.1±4.7 
OVA + PD98,059 6.5±0.1* 94.0±4.0 6.6±0.2 95.8±2.4 7.8±0.1 52.6±3.7 
Control + SB203580 6.3±0.1 92.0±1.8 6.7±0.2 94.8±4.4 7.8±0.1 56.2±4.4 
OVA + SB203580 6.7±0.1* 96.5±1.2 6.8±0.2 96.1±1.8 8.0±0.1 56.2±5.2 
Data presented as mean ±SEM. * represents p<0.05 compared to respective control without OVA. 
DMSO – dimethyl sulfoxide, OVA – ovalbumin, LTE4 – leukotriene E4, PD98,059 – MEK1/2 
inhibitor, SB203580 – p38 inhibitor, SP600125 – JNK inhibitor. Emax  - maximal response an 
agonist can elicit, pEC50 is the –log10 agonist concentration that produces 50% of the agonists 
maximal effect. 
A B C 
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incubated with OVA and DMSO and segments incubated with OVA and SP600125 (Fig. 4) 
(Tab. 1), while Emax for histamine between these two groups was not affected (Fig. 4) (Tab. 
1). There was no significant difference in pEC50 and Emax induced by histamine for the other 
inhibitors (PD98,059 and SD203580) compared to DMSO (Tab. 1). There was no significant 
difference in pEC50 and Emax induced by carbachol or LTE4 for any of the inhibitors compared 
to DMSO (Tab. 1). 
 
Discussion 
Airway hyper-responsiveness (AHR) is a key feature of asthma that is used to describe the 
increased sensitivity of airway smooth muscle (ASM). Involvement of MAPK, ubiquitous 
intracellular signalling proteins, in AHR has been addressed in many recent studies. In this 
study I have investigated AHR to three common mast cell mediators, which has not been 
evaluated before. This study has shown that one single exposure to OVA causes AHR to 
histamine in GPT segments that are previously sensitized to OVA. It also shows that 
inhibition of MAPK JNK abolishes AHR to histamine in GPT that are sensitized and exposed 
to OVA. 
Previous studies 
In previous unpublished studies we have applied histamine receptor and 5-LOX blockers 
before exposure of sensitized GPT to OVA which abolished the contractions in culture. The 
following day during myograph measurements the AHR response to histamine was not 
affected compared to segments not treated with blockers, though the effect of the blockers had 
vanished at time of the measurements. From this, we concluded that AHR after OVA 
exposure did not arise due to one previous contraction in culture. Several studies have, 
 
Figure 4. Contraction induced by histamine presented as dose-response curve for segments 
incubated with OVA and DMSO or OVA and SP600125. DMSO – dimethyl sulfoxide, OVA – 
ovalbumin, SP600125 – JNK inhibitor. Data plotted from Table 1. 
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however, reported that repeated contractions per se can cause AHR, for example Grainge et 
al. (20). 
MAPKs are known to exert their effects through modulating transcription and translation 
(28). Since we were interested in MAPKs involvement in AHR, we inhibited transcription 
and translation using actinomycin D in GPT sensitized and exposed to OVA, which did not 
affect the AHR response (unpublished data). Therefore, we concluded that AHR after OVA 
exposure did not arise due to a change in proteins synthesis.  
JNK, p38 and ERK have in some studies been shown to be involved in inducing AHR to 
acetylcholine-like substances or histamine, however, some studies have found no such 
involvement. Lei et al. have shown that inhibition of JNK using SP600125, but not MEK1/2 
using PD98,059 or p38 using SB203580 attenuates the bronchial constriction in rats to 
thromboxane A, which is a potent airway constrictor (35). Other studies have shown that 
inhibition of p38 using SB239063 (41) or M39 (42) prevented or significantly reduced AHR 
to methacholine in mice sensitized with OVA. Williams et al. have shown that inhibition of 
p38 using SP600125 significantly inhibited ozone-induced AHR to acetylcholine in mice 
(37). Similarly, Duan et al. showed that inhalation of p38α antisense oligonucleotide, which 
binds to and blocks the translation of p38α mRNA, significantly reduced OVA-induced AHR 
to methacholine in challenged mice (43). Sakai et al., on the other hand, have shown that 
another cytokine, tumour necrosis factor alpha, induced AHR to acetylcholine which can be 
abolished by blocking ERK, but not p38 in rat bronchi (44). The role of ERK in AHR is also 
supported by data from Ohnishi et al. (45). 
These conflicting results may partly be explained by the fact that the studies have used 
different animal models. Also, the use of airway tissue from mice and rat makes the results of 
these studies not directly comparable to our study, since the physiopharmacological airway 
properties of these animals differ in many ways (27). Another explanation is that the way of 
measuring AHR varies between different studies discussed above: some groups have used in 
vivo measurements, like airway resistance in living animals, while others have used ex vivo 
tissues. Lastly, different inhibitors of MAPK have been used in these studies to demonstrate 
the involvement of JNK, p38 and ERK in AHR. The fact that not all studies have used the 
same inhibitors and that the inhibitors have a varying specificity affects the possibility to 
compare the results of these studies correctly. The inhibitors SP600125 and PD98,059 have 
been shown to inhibit each other’s primary substrates and several other protein kinases not 
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studied here (32). This implies that the inhibitory effects of SP600125 and SB98,059 
discussed in this study may reflect not only specific inhibition of JNK and p38, but also cross-
inhibition and effects from inhibition of other signalling pathways. However, as mentioned 
previously, the level of inhibition of each other’s primary substrates by SP600125 and 
SB98,059 can be considered low as compared to level of inhibition of the primary target. 
Moynihan et al. studied the Ca2+ response of primary ASM cells to cytokine IL-13, which is 
an important messenger in the early phase of inflammation. They found that Ca2+ signalling 
pattern was not altered significantly by inhibition of p38 signalling, but instead by a 
concurrent inhibition of JNK and ERK (34). Ca2+ signalling is important for ASM contraction 
as described previously and an altering of Ca2+ signalling pattern through MAPK pathways 
can be a possible molecular mechanism behind AHR. Data supporting the findings of 
Moynihan et al. have been obtained by Manson et al. (manuscript in preparation) in isolated 
human bronchi, where two-days incubation with IL-13 caused AHR to histamine. The study 
of Moynihan et al. also highlighted that inhibition of only one pathway may not be enough to 
cause a change in ASM contractile pattern and cause AHR.  
In this study, no AHR to carbachol was detected. Carbachol is a nonselective muscarinic 
receptor agonist (16), much like methacholine, that is used to detect AHR (15), which makes 
this finding quite unexpected. Also, no AHR to LTE4 was detected. There are no studies done 
on AHR to LTE4 or any other leukotriene after sensitization and exposure to allergen, making 
it difficult to compare the results with previous research. However, previous studies have 
shown that pre-treatment of GPT with LTE4 causes AHR to histamine (46, 47). Nevertheless, 
the results from these studies have not been repeatable in our lab. My study also shows that 
the inhibitors themselves do not have any significant effect on the contractile properties of 
ASM of the trachea. This was important to establish to be able to isolate the effects of solely 
MAPK inhibitors on the airway tone.  
Strengths and limitations 
One strength of this study is the use of whole isolated tissue samples from the GT. This model 
allows studying of the isolated ASM without supporting structures and other tissue that it 
might communicate with. However, when the outcome is measured in tissue of a living 
animal, it can vary due to a variety of factors that cannot fully be controlled. In the airway 
tissue, this includes the effects from cytokines and chemokines, attraction of immune cells 
from the blood stream, nerve cell stimulation and effect from other blood-borne substances. 
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On the other hand, the method of measuring AHR in the living animal reflects the actual 
reaction better than the artificial environment in the organ bath. However, in this study I did 
not aim to address the mechanism behind AHR in a living animal, but specifically targeted 
pharmacological properties of the airway contraction in AHR. 
Another strength is the method used, in which strength of the actual contraction can be 
measured in real-time. In these conditions the time between the interventions is based on the 
functional changes in the specific sample, rather than a median estimate of the tissue 
behaviour. In that way, a more individualized approach can be used, which should make the 
results more consistent.  
One more strength of our approach is the animal model, which has been established and 
improved over the past 30 years. In this model, it has been shown that after one sensitization 
and one OVA exposure GP develop AHR to methacholine, late phase inflammation and 
airway inflammation (26). GP’s airway tissue, pharmacology and reactivity have the highest 
similarity to human airway tissue, compared to rats and mice (27). Of course, the optimal 
model for this investigation would be human airway tissue, but the supply is sparse. This 
tissue is usually obtained from patients that undergo lobectomies, which is why it is also 
important to consider other morbidities that can negatively affect the results.  
However, there are several limitations in this study, one of them being the use of trachea 
instead of smaller airways. Most of the inflammation and airway resistance resides in the 
smaller airways that can shut close and cause severe breathing problems (48). Also, some 
pharmacological differences have been noted between different levels of the airway in GP, 
making it hard to extrapolate data from the trachea to all other airways (Belikova M., 
unpublished data). For these reasons, smaller airways can better depict the actual 
physiopharmacological properties of AHR. 
Another limitation is use of only DMSO as control for the incubation with inhibitors. The 
trachea was divided into eight segments with 2-3 cartilage rings in each segment and the 
segments were distributed over eight organ baths. The amount of organ baths and the length 
of the trachea is a limitation that does not allow for more segments to be studied 
simultaneously. Eight segments were treated with one of three inhibitors diluted in DMSO 
and OVA or no OVA. DMSO was added as a vehicle and had to be considered as a separate 
control group, but due to the amount of organ baths only one control for the inhibitors was 
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possible, therefore DMSO was chosen as a control. However, it would have been desirable to 
have a control group without DMSO.  
Last, another limitation is that it is not clear whether the effect on contraction is because of 
action of MAPK in the ASM, or other resident cells in the trachea. The more complex a 
studied tissue is, the less specific is the response elicited by it. So while the contractions 
themselves are mediated by the ASM, it is uncertain if the inhibition of MAPK exerts its 
effects directly in the ASM or in other cells like epithelial cells, fibroblasts or mast cells. 
Significance 
The possibility to induce AHR to histamine in a sensitized guinea pig ex vivo model after one 
exposure to OVA is in line with previous research. Due to use of logarithmic values, a 0.3 
shift in the dose-response curve pEC50 value actually corresponds to 2-fold lower 
concentration of histamine required to reach 50% of the maximal possible contraction. Hence 
segments incubated with OVA respond with an earlier contraction at lower concentrations of 
histamine, which in turn is the core of the AHR phenomena. Likewise, this implies that at one 
given concentration of histamine the trachea with induced AHR will have contracted more, 
which in turn decreases the radius of the airway more than in a trachea without AHR. 
According to Poiseulle law,𝑅 = 8𝜂𝐿/(𝜋𝑟^4 ) , where R is resistance in a pipe, η is viscosity 
of the media, L is the length of the pipe and r is the radius of the pipe. Clearly, a 2-fold 
change in the airway radius has an r4impact on the airflow resistance in the trachea, which can 
be considered great in a clinical setting. No change in Emax however, is interpreted as no 
change in contraction force after sensitisation and exposure to OVA. 
JNK inhibitor SP600125 inhibited the shift in the pEC50 value, ameliorating the OVA-induced 
shift in the dose-response curve. The contribution of JNK, a MAPK that is involved in the 
inflammatory response, to supervening of AHR to histamine is an important contribution to 
understanding this major characteristic of asthma and opens the possible use of JNK 
inhibitors in treating AHR. MAPK inhibitors are already used today for cancer treatment (49), 
thus a vast knowledge base has already been acquired, reducing time and funds for drug 
development.  
Future studies 
This study has highlighted the involvement of JNK MAPK in AHR to histamine, however 
several issues still remain unclear, one of them being the use the JNK inhibitor SP600125, 
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since it has been shown to be somewhat unspecific. There are several other JNK inhibitors 
available that can also be tested in the same setting in order to evaluate if the effect on AHR 
will persist. Other inhibitors for MEK1/2 ERK and p38 may also be tested. Another possible 
future study is use of a combination of MAPK inhibitors on the same segment. This is 
particularly interesting due to the findings of Moynihan et al that only concurrent inhibition of 
ERK and JNK alters Ca (2+) signalling.  
In order to obtain a deeper understanding of the involvement of MAPK in AHR, studies of 
smaller airways are needed, since it is in the smaller airways that the bronchoconstriction has 
most of its effects. We have established a method for using GP primary bronchi in an organ 
bath myograph (unpublished data). Another, more clinically relevant model is, of course, 
human bronchi, which we have an access to and for which we have an adapted methodology. 
In a such study it would be of interest to have bronchi from known asthmatics and non-
asthmatics. 
Lastly, a chronic model, where the GP is repetitively exposed to antigen during a period of 
time would allow for determining if the repetitive bronchoconstriction effects AHR to mast 
cell mediators. This future study would also enable investigation of MAPK involvement. A 
chronic model is also more clinically relevant because there is little chance to prevent the 
supervention of AHR in patients, since most of them already suffer from the symptoms at 
presentation. 
Conclusions 
In this project, tracheal ring segments from GP sensitized to OVA were studied in an organ 
bath myograph. It was found that a single intraperitoneal injection followed by a single 
exposure to ovalbumin caused AHR to histamine in the tracheal segments. Moreover, 
inhibition of JNK MAPK signalling pathway abolished the airway hyper-responsiveness in 
those segments. These findings are important for further understanding of the mechanisms of 
AHR and open up to further investigation of whether MAPK inhibitors can be used as 
treatment for patients suffering from this condition. 
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